Who are Dapagliflozin Farxiga®'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Dapagliflozin + Lobeglitazone, CTM Boost, senfrol monotherapy, B55R1 and B55R2, CDobi, Comparator monotherapy empagliflozin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dapagliflozin-farxiga.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Dapagliflozin Farxiga® — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dapagliflozin Farxiga® (Dapagliflozin Farxiga®) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SGLT2 inhibitor. Area: Diabetes, Cardiovascular.

phase 3 SGLT2 inhibitor SGLT2 (sodium-glucose cotransporter 2) Diabetes, Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Dapagliflozin Farxiga® (Dapagliflozin Farxiga®) — October 6 University. Dapagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney, reducing glucose reabsorption and increasing urinary glucose excretion.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Dapagliflozin Farxiga® TARGET	Dapagliflozin Farxiga®	October 6 University	phase 3	SGLT2 inhibitor	SGLT2 (sodium-glucose cotransporter 2)
Dapagliflozin + Lobeglitazone	Dapagliflozin + Lobeglitazone	Seoul National University Bundang Hospital	marketed	SGLT2 inhibitor + thiazolidinedione combination	SGLT2 and PPAR-γ
CTM Boost	CTM Boost	Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)	marketed	SGLT2 inhibitor	SGLT2
senfrol monotherapy	senfrol monotherapy	Peking University Third Hospital	marketed	SGLT2 inhibitor	SGLT2
B55R1 and B55R2	B55R1 and B55R2	AJU Pharm Co., Ltd.	marketed	SGLT2 inhibitor	SGLT2
CDobi	CDobi	Services Hospital, Lahore	marketed	SGLT2 inhibitor	SGLT2
Comparator monotherapy empagliflozin	Comparator monotherapy empagliflozin	The George Institute	marketed	SGLT2 inhibitor	SGLT2 (sodium-glucose cotransporter 2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (SGLT2 inhibitor class)

Daewon Pharmaceutical Co., Ltd. · 13 drugs in this class
Qilu Pharmaceutical Co., Ltd. · 10 drugs in this class
Takeda · 10 drugs in this class
Taejoon Pharmaceutical Co., Ltd. · 9 drugs in this class
Hanmi Pharmaceutical Company Limited · 9 drugs in this class
Addpharma Inc. · 9 drugs in this class
GlaxoSmithKline · 7 drugs in this class
AO GENERIUM · 7 drugs in this class
Merck Sharp & Dohme LLC · 7 drugs in this class
Nobelpharma · 6 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dapagliflozin Farxiga® — Competitive Intelligence Brief. https://druglandscape.com/ci/dapagliflozin-farxiga. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab